Live Breaking News & Updates on Damien Choplain

Stay updated with breaking news from Damien choplain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript

Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript September 21, 2023 Valneva SE misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.36. Operator: Good day, and thank you for standing by. Welcome to the Valneva Half Year 2023 Financial Results Call and Webcast. [Operator Instructions] Please note that today’s conference is being […] ....

United States , Kingdom Of Bahrain , Thomas Lingelbach , Samir Devani , Suzanne Van Voorthuizen , Damien Choplain , Maury Raycroft , Simon Scholes , Max Herrmann , Pressmaster Shutterstock , Peter Buhler , Instituto Butantan , Bevan Wang , French Market Authority , Exchange Commission , Health Canada , Fast Track Designation , Target Product Profile , Low Cost , Jobs That Pay , Van Voorthuizen , Vaccine Development , Chikungunya Virus , Peter Buhler , Perator Instructions , Product Sales ,

Nicox Reports 2021 Financial Results and First Quarter 2022

Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470. ....

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , Republic Of , United Arab Emirates , City Of , South Korea , Yi Chen , Gavin Spencer , Enregistrement Universel , Damien Choplain , Pharma Bio , Pooya Hemami , Mont Blanc , Robertn Weinreb , Sophia Antipolis , Dylan Van Haaften , Mont Blancphase , Michele Garufi , Sanjayg Asrani , Kepler Cheuvreux , States Europe , Nicox Group ,

Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones

Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470 Mont Blanc Phase 3 clinical ....

Provence Alpes Côd Azur , United States , Hong Kong , France General , United Kingdom , Republic Of , United Arab Emirates , South Korea , Gavin Spencer , Kepler Cheuvreux Damien Choplain , Enregistrement Universel , Pharma Bio , Mont Blanc , Robertn Weinreb , Sophia Antipolis , Mont Blancphase , Sanjayg Asrani , Michele Garufi , States Europe , Nicox Group , University Of California San Diego , Eyevance Pharmaceuticals , Shiley Eye Institute , Edison Investment Research Pooya Hemami London , Nicox Executive Committee , Garnier Co Dylan Van Haaften Paris ,

Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Press ReleaseNicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseMarch 2nd, 2022 - release at 7:30 am CET Sophia ....

United States , Provence Alpes Côd Azur , France General , United Kingdom , Gavin Spencer , Enregistrement Universel , Pharma Bio , Kepler Cheuvreux Damien Choplain , Sophia Antipolis , Michele Garufi , Frank Dellafera , States Europe , Lifesci Advisors , Drug Administration , Head Of Corporate Development , Nicox Fera Partnership , Fera Pharmaceuticals , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Garnier Co Dylan Van Haaften Paris , Sickle Cell , Euronext Paris , Orphan Drug Designation , New Drug Application , Chief Executive Officer , Orphan Drug ,

Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China

Press ReleaseNicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China ZERVIATE (cetirizine ophthalmic solution), 0.24% was non-inferior to comparator ....

United States , Provence Alpes Côd Azur , France General , United Kingdom , South Korea , Gavin Spencer , Enregistrement Universel , Pharma Bio , Kepler Cheuvreux Damien Choplain , States Europe , Sophia Antipolis , Santen Pharmaceutical Co Ltd Of Japan , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Garnier Co Dylan Van Haaften Paris , Partner Ocumension Obtains Positive Phase , Trial Results , Euronext Paris , Chinese Phase , New Drug Application , Chief Business Officer , Far East , Ocumension Therapeutics , Southeast Asian ,